If you have spent an evening researching PRP for knee arthritis, you have probably found two versions of the internet. In one, platelet-rich plasma is the thing that finally worked. In the other, it is an expensive injection that performs about as well as salt water. Both impressions come from real published research, and 2026 has produced several new analyses that explain fairly precisely why.
The short version is uncomfortable, and useful. Across the recent high-quality evidence, a PRP injection on its own tends to produce a change that researchers can measure and patients may not actually notice. The one combination in the 2026 literature where the pain benefit did cross the threshold patients feel involved what happened after the needle came out.
The number that matters is not the p-value
Most arguments about PRP are arguments about statistical significance, which only tells you that a difference probably was not luck. It says nothing about whether the difference is big enough to matter to the person with the knee. Researchers measure that separately, with a threshold called the minimal clinically important difference — the smallest change in a pain or function score that a patient would recognize as an improvement worth having.
So a study can report a statistically significant benefit from PRP and, in the same breath, report that the benefit was smaller than a patient would notice. Both statements are true. Only one of them is about your knee.
What the 2026 network meta-analysis found about injections alone
The most direct evidence comes from a Level I network meta-analysis published in Arthroscopy in July 2026, pooling 24 randomized controlled trials and 2,960 patients. It compared PRP, stromal vascular fraction, bone marrow aspirate concentrate, umbilical cord-derived mesenchymal stem cells, and hyaluronic acid, and it deliberately standardized every outcome against the minimal clinically important difference.
Stromal vascular fraction and bone marrow concentrate reduced pain significantly more than hyaluronic acid at three, six, and twelve months, with mean differences of −0.7 to −1.1. PRP and the cord-derived cells showed modest or non-significant effects, −0.3 to −0.7. Function followed the same ordering. But the authors’ central conclusion is the one worth carrying away: the magnitude of change in both pain and function did not exceed the minimal clinically important difference for any of these injections. In their ranking of final outcomes, PRP placed below the cell-based preparations, with hyaluronic acid last.
The one combination where the pain benefit cleared the bar
A 2026 systematic review and meta-analysis in Disability and Rehabilitation asked a different question: not whether PRP beats another injection, but whether PRP plus structured exercise beats either one by itself. It pooled six randomized trials and 314 people with knee osteoarthritis.
Exercise therapy after PRP reduced pain more than exercise alone, with a short-term mean difference of −2.69 and a long-term standardized mean difference of −0.65. It also reduced pain more than PRP alone: short-term mean difference −2.00, long-term standardized mean difference −1.24. Function improved more than PRP alone in the short term and more than exercise alone in the long term.
Here is the part that connects to the paragraph above. The authors report that the pain reductions exceeded the minimum clinically important difference, while the functional improvements did not. In a literature where almost nothing clears that bar, a pain result that does is genuinely notable — and it came from the combination, not the injection.
How much certainty the authors attached to it
Less than you might hope, and they say so plainly. The six trials were of moderate methodological quality with high risk of bias, and the certainty of evidence was graded low to very low. The authors explicitly caution that these findings should be interpreted carefully and that the functional results limit conclusions about clinical efficacy. This is a promising signal from a small, imperfect body of work, not a settled fact. A published correction to the article also exists and is worth reading alongside it.
Why the same injection gets opposite reviews
There is a structural reason the optimistic version of PRP is easier to find online, and it was quantified this year. A systematic review and spin analysis in Arthroscopy examined the abstracts of 49 systematic reviews and meta-analyses of PRP for knee osteoarthritis, comparing what each abstract claimed against what its own full manuscript showed.
One or more forms of spin appeared in 92% of those abstracts, 45 of 49. The most common was a conclusion that focused selectively on a statistically significant efficacy outcome, present in 63%. Methodological quality was rated high in only 10% of the reviews and critically low in 55%. Lower levels of evidence were associated with inappropriate extrapolation. The authors note that the spin they identified tended to favor the use of PRP.
That is not a reason to dismiss PRP. It is a reason to be skeptical of any summary of PRP research — including a clinic’s — that reads as uniformly enthusiastic.
Two PRP injections are not necessarily the same treatment
A senior state-of-the-art review in the American Journal of Sports Medicine makes a point that undercuts most online comparisons. PRP is not one product. Its biological activity varies with the patient, the preparation technique, and the tissue being targeted, and the review identifies insufficient characterization of PRP in clinical studies as a major limitation — one that hampers both determining whether PRP works for a given condition and understanding its basic biology.
The Current Pain and Headache Reports review lists the same culprits: single versus double-spin technique, leukocyte concentration, platelet concentration. When two trials report different results, they may not have tested the same thing. We wrote about what that means for an individual patient in why PRP results vary so much.
Questions worth asking before you book an injection anywhere
The practical value of this year’s research is that it suggests better questions. These are reasonable to ask any clinic in the Oklahoma City metro, ours included:
- What happens after the injection? If the answer is rest and hope, the 2026 evidence says that plan is leaving the most promising finding on the table.
- Who supervises the exercise portion, and is it a structured program or a handout?
- How is the preparation made, and is it leukocyte-rich or leukocyte-poor? That choice is linked to how sore the joint is afterward.
- What will be measured, at what intervals, and what result would mean this is not working — is there a stopping point?
Our own answer to the first one is a prescribed home exercise program with scheduled follow-up, planned before the injection rather than after it.
Who is generally not a good candidate
PRP is not appropriate for everyone, and candidates are typically evaluated for the following before anything is scheduled:
- Active infection, locally or systemically.
- Blood or platelet disorders, significant anemia, or current anticoagulation that cannot be safely managed around a procedure.
- Active cancer, or current chemotherapy or radiation, without coordination with the treating oncology team.
- Pregnancy or breastfeeding.
- An expectation of a cure, or an inability to participate in the activity and rehabilitation side of the plan, which the 2026 evidence suggests is where much of the benefit lives.
This list is a starting point for a conversation, not a diagnosis. Individual suitability is determined during an in-person evaluation.
Frequently asked questions
Does PRP cure knee arthritis?
No. Nothing currently available cures osteoarthritis, and no honest clinic should tell you otherwise. PRP is studied as a way to reduce pain and support function in a joint that has already changed structurally. The 2026 network meta-analysis found that the pain and function changes from orthobiologic injections, PRP included, did not exceed the minimal clinically important difference compared with hyaluronic acid through twelve months.
Is PRP for knee arthritis FDA-approved?
The devices used to spin blood into platelet-rich plasma are FDA-cleared, but PRP is not an FDA-approved treatment for knee osteoarthritis or for joint and tendon pain generally. Any clinic describing it as FDA-approved for your knee is overstating the regulatory picture.
Is PRP or a cortisone injection better for knee arthritis?
It depends almost entirely on when you measure. The 2026 Current Pain and Headache Reports review concluded that corticosteroid injections provide superior short-term relief, while PRP offers more sustained medium and long-term pain relief and functional improvement. Steroid also carries potential structural adverse effects with repetition. Neither is simply better; they have different shapes over time, which we covered in more detail in our piece on PRP versus cortisone.
How soon after a PRP injection can I start exercise?
That is a question for whoever performs the injection, because it depends on the joint, the findings, and what else is going on. What the research shows is that this question matters more than it is usually treated as mattering: in the 2026 systematic review, the trials that added structured exercise therapy after PRP reported better pain outcomes than either PRP alone or exercise alone. At Venturis, patients are given a prescribed home exercise program and followed up on it rather than handed a sheet and sent away.
What side effects are common after a PRP knee injection?
A 2026 systematic review of 32 randomized trials covering 1,268 PRP-treated knees found adverse events reported in 18.7% of PRP cases, most commonly mild knee pain and swelling at 10.6%. Those rates were significantly higher than hyaluronic acid for mild pain and swelling, and that difference held only for leukocyte-rich preparations — leukocyte-poor PRP looked similar to hyaluronic acid. No severe adverse events were reported in any group.
Can PRP help me avoid knee replacement surgery?
The research discussed here did not study that question. These analyses measured pain and function against other injections over three to twelve months; none of them tracked whether patients went on to have a joint replaced. Some patients do want to explore non-surgical options before committing to surgery, and that is a reasonable thing to discuss during an evaluation.
Talk through whether PRP makes sense for your knee
If you are weighing an injection for knee arthritis and want a straight read on what the evidence does and does not support for your particular joint, we are glad to talk it through. Dr. Alvin Philipose has practiced regenerative and functional medicine for over 25 years. You can learn more about our PRP therapy in Oklahoma City or book a free 15-minute phone consultation.
Venturis Clinic
7917 N May Ave, Suite B
Oklahoma City, OK 73120
(405) 848-7246
This content is for educational purposes only and is not medical advice, diagnosis, or treatment. Individual results vary and no outcome is guaranteed. Venturis Clinic offers regenerative, functional, and alternative medicine services; some therapies discussed are not FDA-approved for the uses described. Talk with a qualified healthcare provider about your specific situation before beginning any treatment.
Sources
- Han JH, Jung M, Chung K, Moon HS, Jung SH, Kim SH. Intra-articular orthobiologics show statistically but not clinically meaningful improvements compared with viscosupplementation in knee osteoarthritis: a network meta-analysis of randomized controlled trials. Arthroscopy. 2026;42(10):2291–2308. doi:10.1002/arj.70411
- Dasdemir KA, Karatas N. The effect of combined platelet-rich plasma and exercise on pain and function in knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials. Disability and Rehabilitation. 2026;1–16. doi:10.1080/09638288.2026.2674613 (Correction: doi:10.1080/09638288.2026.2684871)
- Fullano GD, Greenstein MD, Klosterman EL, Hartwell MJ. Statistically significant results favored in abstracts of platelet-rich plasma treatment of knee osteoarthritis: a systematic review and spin analysis. Arthroscopy. 2026;42(1):349–360. doi:10.1002/arj.70027
- Abril M, Alonso B, Ku JB, Pak R, Rosenblum D. Platelet-rich plasma in chronic joint pain: an autologous alternative to steroids. Current Pain and Headache Reports. 2026;30(1):92. doi:10.1007/s11916-026-01524-1
- Rothrauff BB, Featherall JT, Uppstrom TJ, et al. Platelet-rich plasma in the treatment of musculoskeletal disease in 2025 and beyond. The American Journal of Sports Medicine. 2026;54(8):2058–2074. doi:10.1177/03635465251395284
- Nakagawa HF, Kim J, Rabinowitz J, Sussman WI. Assessment of adverse events and safety associated with intra-articular platelet-rich plasma injections compared to other injectates for knee osteoarthritis: a systematic review and meta-analysis. PM&R. 2026;18(9):1072–1084. doi:10.1002/pmrj.70141
